Endogenous sodium-potassium-chloride cotransport inhibitor in congestive heart failure. 1996

J L Dubois-Randé, and O Montagne, and M Alvarez-Guerra, and C Nazaret, and B Crozatier, and P Gueret, and A Castaigne, and R P Garay
INSERM U400, Créteil, France.

OBJECTIVE This study sought to evaluate the relation, if any, between fluid overload in congestive heart failure (CHF) and a newly discovered endogenous natriuretic factor acting like loop diuretic drugs: cotransport inhibitory factor (CIF). BACKGROUND The humoral mechanisms regulating volume overload in CHF are not fully understood. Therefore, we investigated whether there is a role for CIF in this pathologic condition. METHODS Plasma and urinary CIF levels were investigated in 23 patients with chronic CHF and compared with changes in plasma atrial natriuretic peptide (ANP). Twelve patients without CHF served as control subjects. RESULTS CHF was associated with a highly significant threefold increase in both plasma CIF levels (mean +/- SD 7.10 +/- 3.01 vs. 2.28 +/- 0.92 U/ml, p < 0.0001) and urinary CIF excretion (7,849 +/- 3,600 vs. 2,351 +/- 1,297 U/day, p < 0.0001) with respect to patients without CHF. CIF increased as a function of impairment in left ventricular ejection fraction (r = -0.703, p < 0.0001) and the severity of clinical status. Plasma ANP was also increased in patients with CHF, although to a lesser extent (68%, p = 0.0501) than plasma CIF, and was also significantly correlated with left ventricular ejection fraction (r = -0.552, p = 0.0004). CONCLUSIONS Plasma and urinary CIF activities were strongly and very significantly increased in chronic CHF. In addition to ANP, this long-term natriuretic agent may be of potential importance in reducing fluid overload in CHF.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009320 Atrial Natriuretic Factor A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS. ANF,ANP,Atrial Natriuretic Peptide,Atrial Natriuretic Peptides,Atriopeptins,Auriculin,Natriuretic Peptides, Atrial,ANF (1-126),ANF (1-28),ANF (99-126),ANF Precursors,ANP (1-126),ANP (1-28),ANP Prohormone (99-126),ANP-(99-126),Atrial Natriuretic Factor (1-126),Atrial Natriuretic Factor (1-28),Atrial Natriuretic Factor (99-126),Atrial Natriuretic Factor Precursors,Atrial Natriuretic Factor Prohormone,Atrial Natriuretic Peptide (1-126),Atrial Pronatriodilatin,Atriopeptigen,Atriopeptin (1-28),Atriopeptin (99-126),Atriopeptin 126,Atriopeptin Prohormone (1-126),Cardiodilatin (99-126),Cardiodilatin Precursor,Cardionatrin I,Cardionatrin IV,Prepro-ANP,Prepro-CDD-ANF,Prepro-Cardiodilatin-Atrial Natriuretic Factor,Pro-ANF,ProANF,Proatrial Natriuretic Factor,Pronatriodilatin,alpha ANP,alpha-ANP Dimer,alpha-Atrial Natriuretic Peptide,beta-ANP,beta-Atrial Natriuretic Peptide,gamma ANP (99-126),gamma-Atrial Natriuretic Peptide,Natriuretic Peptide, Atrial,Peptide, Atrial Natriuretic,Peptides, Atrial Natriuretic,Prepro ANP,Prepro CDD ANF,Prepro Cardiodilatin Atrial Natriuretic Factor,Pro ANF,alpha ANP Dimer,alpha Atrial Natriuretic Peptide,beta ANP,beta Atrial Natriuretic Peptide,gamma Atrial Natriuretic Peptide
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D002712 Chlorides Inorganic compounds derived from hydrochloric acid that contain the Cl- ion. Chloride,Chloride Ion Level,Ion Level, Chloride,Level, Chloride Ion
D005260 Female Females
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J L Dubois-Randé, and O Montagne, and M Alvarez-Guerra, and C Nazaret, and B Crozatier, and P Gueret, and A Castaigne, and R P Garay
January 2000, Physiological reviews,
J L Dubois-Randé, and O Montagne, and M Alvarez-Guerra, and C Nazaret, and B Crozatier, and P Gueret, and A Castaigne, and R P Garay
September 1985, The American journal of physiology,
J L Dubois-Randé, and O Montagne, and M Alvarez-Guerra, and C Nazaret, and B Crozatier, and P Gueret, and A Castaigne, and R P Garay
December 1949, Southern medical journal,
J L Dubois-Randé, and O Montagne, and M Alvarez-Guerra, and C Nazaret, and B Crozatier, and P Gueret, and A Castaigne, and R P Garay
January 1998, Uspekhi fiziologicheskikh nauk,
J L Dubois-Randé, and O Montagne, and M Alvarez-Guerra, and C Nazaret, and B Crozatier, and P Gueret, and A Castaigne, and R P Garay
May 1991, Journal of neurochemistry,
J L Dubois-Randé, and O Montagne, and M Alvarez-Guerra, and C Nazaret, and B Crozatier, and P Gueret, and A Castaigne, and R P Garay
January 1966, Clinica chimica acta; international journal of clinical chemistry,
J L Dubois-Randé, and O Montagne, and M Alvarez-Guerra, and C Nazaret, and B Crozatier, and P Gueret, and A Castaigne, and R P Garay
March 1988, Japanese heart journal,
J L Dubois-Randé, and O Montagne, and M Alvarez-Guerra, and C Nazaret, and B Crozatier, and P Gueret, and A Castaigne, and R P Garay
August 1952, The American journal of the medical sciences,
J L Dubois-Randé, and O Montagne, and M Alvarez-Guerra, and C Nazaret, and B Crozatier, and P Gueret, and A Castaigne, and R P Garay
January 1998, Life sciences,
J L Dubois-Randé, and O Montagne, and M Alvarez-Guerra, and C Nazaret, and B Crozatier, and P Gueret, and A Castaigne, and R P Garay
January 1950, Acta medica Scandinavica. Supplementum,
Copied contents to your clipboard!